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ABSTRACT Signal-transduction pathways mediated by
guanine nucleotide-binding regulatory proteins (G proteins)
determine many of the responses of hematopoietic cells. A
recently identified gene encoding a G protein a subunit, Gal6,
is specifically expressed in human cells of the hematopoietic
lineage. The Gal6 cDNA encodes a protein with predicted Mr
of 43,500, which resembles the Gq class of a subunits and does
not include a pertussis toxin ADP-ribosylation site. In com-
parison with other G protein a subunits, the Gal6 predicted
protein has distinctive amino acid sequences in the amino
terminus, the region A guanine nucleotide-binding domain,
and in the carboxyl-terminal third of the protein. Cell lines of
myelomonocytic and T-cell phenotype express the Gal6 gene,
but no expression is detectable in two B-cell lines or in
nonhematopoietic cell lines. Gal6 gene expression is down-
regulated in HL-60 cells induced to differentiate to neutrophils
with dimethyl sulfoxide. Antisera generated from synthetic
peptides that correspond to two regions of Gal6 specifically
react with a protein of 42- to 43-kDa in bacterial strains that
overexpress Gal6 and in HL-60 membranes. This protein is
decreased in membranes from dimethyl sulfoxide-differenti-
ated HL-60 cells and is not detectable in COS cell membranes.
The restricted expression of this gene suggests that Gal6
regulates cell-type-specific signal-transduction pathways,
which are not inhibited by pertussis toxin.
Hematopoietic cells have the capacity to sense environmen-
tal stimuli and generate specific responses to infection and
hemorrhage. Many of these responses are regulated by
guanine nucleotide-binding regulatory proteins (G proteins),
membrane-associated proteins that transduce signals from
cell-surface receptors to intracellular effectors. The nucle-
otide-binding proteins within this class are heterotrimers,
consisting of an a subunit that binds guanine nucleotides, a
,B subunit, and a y subunit. A wide range of biochemical
responses are regulated by G proteins, and a specific family
of transmembrane receptors is proposed to interact with G
proteins (for review, see refs. 1-3). The versatility of G
protein-mediated signal transduction is reflected in the di-
versity of genes encoding the G protein subunits (4-5).
Hematopoietic cells are known to express several different
G proteins. In neutrophils and monocytes, G proteins medi-
ate the stimulation of phospholipid hydrolysis and the sub-
sequent inflammatory response induced by chemotactic li-
gands (6, 7). These ligands trigger intracellular events that
show different degrees of sensitivity to pertussis toxin (Bor-
detella pertussis islet-activating protein), a bacterial toxin
that inhibits G protein function by ADP-ribosylating the a
subunit of the heterotrimer (1, 8, 9). The complex patterns of
signal transduction manifested by these cells suggest that
they could result from the actions of multiple G proteins (5,
10, 11).
We have identified a G protein a subunit, Gal6, that is
specifically expressed in human cells of hematopoietic lin-
eage. *
MATERIALS AND METHODS
Molecular Cloning. Total RNA from HL-60 human promy-
elocytic leukemia cells was reverse-transcribed to cDNA,
then amplified by means of PCR. Primers for the PCR were
degenerate oligonucleotides corresponding to two regions
highly conserved among G protein a subunits (12). The PCR
products were cloned into the pGEM4z plasmid (Promega)
and analyzed byDNA sequencing (13). The PCR fragment for
Gal6 was radiolabeled and used to probe A gtlO cDNA
libraries by plaque hybridization (14). Gal6 cDNA clones
were analyzed by DNA sequencing of both strands by using
synthetic oligonucleotides as primers. The Gal6 predicted
protein was aligned with other mammalian G protein a
subunits by using the programs GAP, BESTFIT, and FASTA in
the GCG sequence analysis package.
Cell Culture. Hematopoietic cell lines HL-60 (15, 16), KG-1
(17), KG-la (18), KCL22 (19), THP-1 (20), and Raji (21),
provided by H. P. Koeffler and M. C. Territo (University of
California, Los Angeles, Department of Medicine), were
maintained at a density of 5 x 104 to 106 cells per ml in RPMI
1640 medium/10%o fetal bovine serum (GIBCO)/penicillin at
100 units/ml/streptomycin at 100 ,ug/ml/2 mM L-glutamine.
Other cell lines were obtained from the American Type
Culture Collection (Rockville, MD) and maintained as rec-
ommended (21-23). HL-60 cells (approximate passage 60) at
a density of 3 x 105 were induced to differentiate by incu-
bation with 1.3% dimethyl sulfoxide for 2-5 days (24). After
5 days of exposure, 80% of the cells reduced nitroblue
tetrazolium (NBT) when stimulated with phorbol ester, and
50% of the cells reduced NBT after exposure to the chemo-
tactic peptide fMet-Leu-Phe.
RNA Analysis. RNA was extracted using phenol and
guanidium thiocyanate at 60°C (refs. 14 and 25, as modified
by M. B. Raines, University of California, Los Angeles,
Department of Medicine) and then purified by banding with
cesium trifluoroacetate (Pharmacia). Samples containing
10-30 ,ug of total RNA were prepared as in ref. 26, separated
by electrophoresis in a formaldehyde/agarose gel, trans-
ferred to Nytran filters (Bethesda Research Laboratories) by
capillary blotting, and crosslinked by UV irradiation
(Stratalinker, Stratagene). Filters were prehybridized and
then hybridized at 420C with 32P-labeled cDNA probes (1-2
x 106 cpm/ml) for 12-48 hr, in 50o (vol/vol) formamide/500
Abbreviations: G protein, guanine nucleotide-binding regulatory
protein; G, and Gi, stimulatory and inhibitory G protein, respec-
tively.
*The sequence reported in this paper has been deposited in the
GenBank data base (accession no. M63904).
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mM sodium phosphate, pH 7.2/5% SDS/1% bovine serum
albumin/1 mM EDTA (ref. 27, as modified by J. Lem,
California Institute of Technology, Pasadena, CA). Probes
were labeled by primer extension from random hexanucle-
otides to a specific activity of 5 x 108 to 109 cpm/;zg (28).
Filters were rinsed in 0.1-0.2x standard saline citrate (SSC)/
0.1% SDS at 650C and then exposed to x-ray film at -70'C
with an intensifying screen. The level ofRNA expression was
quantitated by laser densitometry (LKB 2202 Ultroscan
transmission laser densitometer) on autoradiograms in a
linear range of exposure. RNA blots were stripped of probe
by incubation in 0.01 x SSC/0. 1% SDS at 100'C for 20 min
(1x SSC is 150 mM NaCl/15 mM sodium citrate, pH 7).
The Ga16 3' untranslated region probe was derived from
nucleotides 1180-1805 of the Ga16 cDNA; 3-actin probe was
derived as described in ref. 29; G protein 31 probe was
derived from HL-60 cells (30). The Gi2 probe was derived
from the 3' untranslated region of a human Gi2 cDNA clone
isolated from HL-60 cells and corresponded to nucleotides
1328-1664 (31).
Protein Analysis. HL-60 cells and COS cells were rinsed in
phosphate-buffered saline and harvested by centrifugation at
1000 x g. Cells were suspended in TED-AP (10 mM Tris, pH
8/1 mM EDTA/1 mM dithiothreitol/1 mM phenylmethylsul-
fonyl fluoride/aprotinin at 50 kallikrein inhibitory units/ml/
pepstatin at 0.7 ,ug/ml/leupeptin at 0.5 ,g/ml) at 4°C and then
lysed by five passes with a hand Dounce homogenizer
(Kontes). Nuclei were pelleted by centrifugation at 500 x g
for 10 min; then the supernatant was centrifuged at 100,000
x g for 30 min. The pellet (crude membranes) was resus-
pended in TED-AP, and protein content was determined
(Bio-Rad protein assay). Samples containing 30-100 ,ug of
membrane protein were resolved on discontinuous buffer
SDS/polyacrylamide gels, electroblotted to nitrocellulose
membranes, and probed with rabbit antisera (32).
Antisera to synthetic peptides were prepared as in ref. 32
and then affinity-purified by binding to an Affi-Gel 10 column
(Bio-Rad) conjugated with the synthetic peptides, eluting
with 3 M sodium thiocyanate, and dialyzing in 10 mM
phosphate buffer.
Expression of Gal6 cDNA in Escherichia coli. The Gal6
cDNA clones were ligated and cloned into the vector pBlue-
script KS (Stratagene), and the construction was verified by
sequencing ofthe ligation sites. A fragment that contained the
complete coding sequence was subcloned into vector NpT7-5
(33), and the resulting plasmid was used for transformation of
E. coli strain BL-21/DE3, a T7 lysogen in which the T7
polymerase is driven by the lac UV-5 promoter (34). For
expression of the recombinant Gal6 protein, this bacterial
strain (BL-21/Gal6) was grown at 30°C to an OD of 1.5, then
isopropyl /3-D-thiogalactoside was added to a final concen-
tration of 0.3 mM, and incubation was continued for another
2 hr. Cells were harvested by centrifugation and stored at
-70°C, then suspended in 10 mM Tris, pH 8/1 mM EDTA/1
mM dithiothreitol/1 mM phenylmethylsulfonyl fluoride,
lysed with a French pressure cell, and centrifuged at 30,000
x g for 1 hr. Bacterial proteins were analyzed by immuno-
blotting as above. More than 50% of the recombinant Ga16
protein remained in the supernatant fraction of the bacterial
lysate.
RESULTS
Molecular Cloning of Ga16 cDNA. Amplification of HL-60
RNA by the PCR produced PCR fragments corresponding to
the previously identified inhibitory (Gi) and stimulatory (Gs)
a subunits UQ2, Gi3, Gs, and the human homologue of Gq (1,
31, 35, 36). A PCR fragment encoding another G protein a
subunit, Gal6, was also isolated and subsequently used
to screen HL-60 cDNA libraries. Plaques (6 x 105) from a
cDNA library derived from HL-60 cells treated with cAMP
were screened to isolate 25 cDNA clones including 22H (Fig.
1B). A 5' region of 22H was used to isolate clone SB from an
undifferentiated HL-60 cDNA library. Oligonucleotide and
cDNA probes from SB were then used to screen 5 x 106
plaques to isolate cDNA clone 19A, which extends from the
5' untranslated region of Gal6 to an EcoRI site at position
676.
The sequence of the Gal6 cDNA constructed from over-
lapping cDNA clones is shown in Fig. 1A, and significant
features of the primary structure are highlighted in Fig. 1 C
and D. The Gal6 cDNA encodes a protein with a predicted
molecular mass of 43,500, which shows 40% amino acid
identity with Gs and 45% identity with members of the Gi
class of G proteins. Gal6 can be grouped with the Gq class
of G proteins because it shares 57% amino acid sequence
identity with Gall and Gq (36). The amino acid sequences
that are conserved in the GTPase class of proteins and that
have been implicated in guanine nucleotide binding are found
in Gal6 (Fig. 1C, sequences denoted A, C, E, G, and I) (1,
37, 38). Also present is a conserved arginine (R) residue at
position 186, which is homologous to the cholera toxin
ADP-ribosylation site in Gs. Gal6 is not a predicted substrate
for ADP-ribosylation by pertussis toxin because it lacks a
cysteine residue four amino acids from the carboxyl terminus
(1-5).
Gal6 is a G protein a subunit with distinctive features. The
sequence in region A differs from other reported G proteins
by the presence of a proline, rather than alanine or threonine,
at amino acid 50 (Fig. 1 C and D; refs. 4 and 5). The sequence
in this region, GPGESGK, has also been found in a murine
G protein a subunit (GalS), which is structurally related to
Gal6 (T. Wilkie and M.I.S., unpublished data). The region A
domain is important for GTP binding and for the endogenous
GTPase activity of G proteins. Two G proteins with a
divergent sequence in this region, G, and Gq, have decreased
ability to hydrolyze GTP and decreased guanine nucleotide
binding in comparison with Gs and G proteins of the Gi class
(39, 40). Other domains known to be important to GTPase
activity, region C and the region adjacent to Arg-186, are
conserved in Gal6 (1, 37).
The Gal6 predicted protein includes two inserts of seven
amino acids in the carboxyl terminal region, when optimally
aligned with other G protein a subunits (Fig. 1D). The first
insert (amino acids 317-323) is similar to the corresponding
region of Gs. The second insert region (amino acids 331-337)
includes several charged amino acids and is not homologous
with other G protein a subunits. These inserts are in a domain
that has been proposed to determine the interaction of G
proteins with effectors (38, 41). The primary structure of G
protein a subunits varies widely in this region, which is the
site of alternative splicing in Go, and in Gs includes an exon
that is not homologous with other G protein genes (42-44).
The amino-terminal region of the Gal6 predicted protein
diverges from the sequence of other reported G protein a
subunits (Fig. 1D). The initiation methionine is in the context
of the consensus sequence for translational initiation pro-
posed by Kozak (45) and is preceded by a termination codon
in the same reading frame (bases -13 to -15). In contrast
with G proteins of the Gi class, Gal6 is not a predicted
substrate for modification by N-myristoylation, as it lacks a
glycine at position 2 (46).
These features of the Gal6 sequence imply that the Gal6
protein could manifest specific properties in signal transduc-
tion. To further explore the function of Gal6, we examined
the pattern of expression of the Gal6 gene in a variety of
human cells.
Expression of Ga16 in Human Cell Lines. The Ga16 gene is
expressed in a lineage-specific pattern in human cell lines
with the phenotype of hematopoietic cell precursors (Fig. 2).
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FIG. 1. Sequence of Gal6 cDNA and features of Gal6 predicted protein. (A) Nucleotide sequence ofGal6 cDNA showing predicted protein
sequence. (B) Gal6 cDNA clones aligned with the complete Ga16 cDNA. Stippled region is coding sequence; hatched bars are 5' and 3'
untranslated regions. P, Pst I; R, EcoRI. (C) Sequence of the Gal6 predicted protein. This sequence is compared with the consensus amino
acid sequence derived from other reported mammalian G protein a subunits (second row). Guanine nucleotide-binding domains A, C, E, G,
and I are marked (4, 37). (D) Significant structural features of Ga16 predicted protein. Ga16 is compared with the amino-terminal region (a);
region A guanine nucleotide-binding domain (b); and carboxyl-terminal region (c) of G proteins representative of each G protein class.
A 2.2-kilobase (kb) Gal6 transcript is evident on Northern examined by Northern blotting (Fig. 2). Human B-cell lines
(RNA transfer) blots of RNA from human myeloid leukemic Raji and IM-9 also do not express Gal6 (21). K-562, a chronic
cell lines HL-60 (16), KG-1 (17), KGla (18), and KCL22 (19). myelogenous leukemia cell line with erythroid and mega-
Gal6 expression was also seen in T-cell lines CEM and karyocytic differentiation potential similar to that of HEL,
Molt-4 (21) and at lower levels in human erythroleukemia cell does not express Gal6 (22).
line HEL (23) and in the monocytic cell line THP-1 (20). In The highest levels of expression of Gal6 were found in
contrast, no Ga16 expression was detected in RNA from a committed myeloid precursor cells of promyelocytic (HL-60)
human fibrosarcoma cell line (HT1080), adrenal carcinoma or myeloblast (KG-1) phenotype. To further define Ga16
cell line (SW13), or in 13 other nonhematopoietic cell lines expression in the myeloid lineage, we prepared RNA from
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FIG. 3. G protein expression in
HL-60 cells differentiated towards neu-
trophils. Autoradiogram of Northern blot
of 30 jig of total RNA from undifferenti-
ated HL-60 cells (lane 0), HL-60 cells
exposed to 1.3% dimethyl sulfoxide for 2
days (lane 2), HL-60 cells exposed to
1.3% dimethyl sulfoxide for 5 days (lane
5). Blot was probed with Ga16 (A), then
stripped, and reprobed with GQ2 3' un-
translated probe (B). (C) Photograph of
ethidium bromide-stained RNA gel be-
fore transfer.
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FIG. 2. Gal6 RNA expression in human cell lines. (A) Northern
blot generated with 10 ,ug ofRNA from cells as listed for the following
lanes: a, KG-la; b, KG-1; c, HL-60; d, KCL22; e, CEM; f, Molt-4;
g, HEL; h, K562; i, HT1080;j, SW13; k, Raji; and 1, IM-9. Lanes m
and n are from a separate Northern blot generated with 30 ,g ofRNA
from cells HL-60 and THP-1, respectively. The blots were hybridized
with a cDNA probe derived from the 3' untranslated region of Gal6
(A), then stripped and hybridized with human ,9 actin probe (B, lanes
a-i) or a probe derived from the human ,1 G protein subunit (B, lanes
m and n). No expression of Gal6 was seen in Northern blots
generated with 15-30 ug of RNA from WiDR or CoilS colon
adenocarcinoma cells, RD or HT117 rhabdomyosarcoma cells,
HT161 osteosarcoma cells, Y79 retinoblastoma cells, LAN-1 or
HT230 neuroblastoma cells, A875 or HS294 melanoma cells, A172
glioblastoma cells, Adl2-transformed fetal retinal cells, or MRC-5
diploid human fibroblasts. These RNA samples all showed abundant
expression of .3-actin. (C) Expression of Gal6 in human hemato-
poietic -cell lines. Phenotypes of cell lines representative of each
lineage are described in refs. 15-23. T, T lymphocyte; B, B lym-
phocyte; Er, erythroid; Mg, megakaryocytic; PMN, neutrophil; Mo,
monocyte (14). Cell lines were graded for degree of expression of
Gal6 as -, +, or + +. DMSO, dimethyl sulfoxide.
HL-60 cells induced towards neutrophil differentiation with
dimethyl sulfoxide (24). In these terminally differentiated
cells, the expression of Gal6 RNA was decreased to 10.5%
(± 3.5% SEM for four separate differentiation experiments)
ofthe level seen in undifferentiated cells. In contrast, expres-
sion of the a subunit of Gi2 increased with differentiation by
160%6 (± 8% SEM for three experiments) relative to levels in
undifferentiated cells (Fig. 3). These results suggest that the
Gi2 and Gal6 genes are divergently regulated in individual
HL-60 cells when this clonal population of cells is induced to
differentiate.
Ga16 Protein. To study expression of the Gal6 protein, we
generated antisera against synthetic peptides identical to
regions of the Gal6 predicted protein. Two peptides were
studied: peptide D3, corresponding to residues 327-344 of
Gal6 (GSKKGARSRRLFSHYTC), and peptide CT55 (C-
RDSVLARYLDEINLL), which corresponds to the carboxyl
terminus of Gal6. Rabbit antisera to these peptides were
affinity purified and shown to react with recombinant Gal6
overexpressed in the bacterial strain BL21/Gal6, specifi-
cally recognizing a protein of 42-43 kDa on immunoblots
(Fig. 4). Both antisera also recognized a protein band of42-43
kDa in immunoblots of membrane fractions from undiffer-
entiated HL-60 cells. The levels of this protein were de-
creased in membrane fractions from HL-60 cells induced to
differentiate by exposure to dimethyl sulfoxide for 5 days and
were undetectable in COS cell membrane fractions (Fig. 4).
Reactivity of each antiserum with the 42- to 43-kDa protein
was inhibited by preincubation of antisera with the immu-
nizing peptide. The fact that two antisera derived from
distinct regions of the Gal6 protein specifically reacted with
a common protein in HL-60 membranes, which was identical
in size with recombinant Ga16, suggests that this 42- to
43-kDa protein is Ga16.
DISCUSSION
The restricted expression of the Ga16 gene suggests that
Gal6 plays a role in signal-transduction pathways that are
specific to myelomonocytic cells and T cells. The Ga16
expression pattern is unique among G proteins. Other G
a b c a e ;
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FIG. 4. Expression of Gal6 protein. Immunoblots were probed
with affinity-purified antisera to synthetic peptides. Lanes: a, b, h,
and i, bacterial strain BL21/Gal6 induced isopropyl with ,B-D-
thiogalactoside (50 gg of protein); c, d, e, and j, HL-60 membranes
(100 Ag of protein); f and k, membranes from dimethyl sulfoxide-
differentiated HL-60 cells (100 ,g of protein); g and 1, COS cell
membranes, 100 Ag. Lanes a-g were probed with a 1: 200 dilution of
antiserum CT55; lanes h-l were probed with a 1: 100 dilution of
antiserum D3. Lanes b and d, antibody reaction was blocked by
preincubation of antiserum with peptide CT55 at 10 ,&g/ml. Lane i,
antibody reaction was blocked by preincubation of antiserum with
peptide D3 at 5 Ag/ml.
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protein a subunits that are present in HL-60 cells and in
mature myeloid cells, GQ2, GQ3, G5, and Gq, are also found in
nonhematopoietic cells and a variety of tissues (1, 31, 35, 36).
Several G protein a subunits are known to change in expres-
sion with differentiation of mammalian cells (47-49). How-
ever, the Gal6 gene must be subject to additional regulatory
processes. Gal6 is expressed only in hematopoietic cells.
Within the myeloid lineage, Gal6 expression is further spec-
ified, as it is down-regulated during terminal differentiation of
HL-60 cells induced by dimethyl sulfoxide. The pattern of
Gal6 expression in other myeloid differentiation pathways
has not yet been defined. In lymphoid cells, Gal6 expression
is again lineage-specific. T-cell lines express Gal6 RNA at
high levels, whereas Gal6 expression was not detected in
two B-cell lines with lymphoblast (Raji) or plasmacytoma
(IM9) phenotypes.
In HL-60 cells, a change in G protein gene expression and
in G protein repertoire parallels a coordinated developmental
change. Induction of terminal differentation by incubating
these cells with dimethyl sulfoxide is associated with an
increase in expression of the G2 a subunit and a decrease in
expression of Gal6. This occurs as cells acquire specific
signal-transduction systems and morphological features char-
acteristic of neutrophils while losing the capacity to proliferate
and to differentiate to monocytes or eosinophils (15, 24). The
pattern of G protein gene expression in this cell line may
indicate that Gal6 is involved in regulating signal-transduction
processes that are not active in neutrophils but are manifested
in other classes of leukocytes or in hematopoietic precursor
cells.
The protein encoded by the Ga16 gene lacks a pertussis
toxin ADP-ribosylation site. This fact is of special interest
because of the increasing appreciation of G protein-mediated
phenomena that are not inactivated by pertussis toxin (1-5).
Mature cells of the lineages that express Gal6 manifest
specific signal-transduction pathways that have been the
subject of intense study (6-11, 50, 51). Gal6 could regulate
pertussis toxin-resistant signaling processes in these cells (8,
9, 52-54). The pattern of Gal6 expression is also consistent
with a role in hematopoietic cell proliferation or differentia-
tion. The cell lines that express Ga16 are capable ofindefinite
proliferation and have the potential to develop along several
pathways. These cell lines are similar in phenotype to normal
hematopoietic progenitor cells and in certain cases can be
induced to differentiate in vitro into cells with the properties
of normal leukocytes (15-23). These attributes of the hema-
topoietic system will allow definitive studies on the regulation
of the Ga16 gene and the role of the Gal6 protein in the
physiology of myeloid cells and T cells.
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